Tasigna cleared for first-line CML use in Japan
This article was originally published in Scrip
Japan's ministry of health, labour and welfare has confirmed the formal approval of Novartis' Tasigna (nilotinib) for first-line use in chronic myeloid leukaemia (CML), making it only the third such approval for the product worldwide.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.